Access Official Technical PDF

Share Summary:LinkedInEmail

Portable medicine quality screening can help medicines regulatory authorities (MRAs), procurement teams and other supply-chain stakeholders assess suspicious products before samples reach a formal laboratory. The devices use a range of analytical methods, from spectroscopy to color tests and chromatography. But portability alone does not establish whether a tool can reliably detect poor-quality medicines in real operating conditions. Evidence on performance, training and appropriate deployment is essential.

A systematic review of scientific studies published up to April 30, 2018 identified 41 portable devices covering 19 technologies. The devices ranged from handheld instruments to single-use lab-on-a-chip tests. Only six had been evaluated in field settings, highlighting a central challenge for decision-makers: promising laboratory results do not necessarily answer how a device will perform during routine surveillance.

What portable medicine quality screening can reveal

Screening devices do not all assess the same features. Some analyze the medicine’s chemical formulation, including the active pharmaceutical ingredient (API) and excipients. Others target a specific API, estimate its amount, or examine physical characteristics such as packaging and tablet appearance. A separate laboratory method, such as high-performance liquid chromatography (HPLC), may still be needed to confirm a screening result.

Spectroscopic instruments—including Raman, near-infrared (NIR) and mid-infrared (MIR) devices—measure how a sample interacts with light. The resulting spectrum acts as a chemical fingerprint, which software compares with reference measurements. This can make testing non-destructive and reduce the need for consumables. However, effective identification depends on having an appropriate reference library, and quantitative analysis may require complex, API-specific calibration models.

Other approaches involve more sample preparation or consumables. Thin-layer chromatography (TLC), colorimetric reactions, paper-based tests and immunoassay dipsticks can identify or estimate targeted ingredients. These methods may be less dependent on electronic spectral libraries, but often require the medicine to be altered or dissolved as part of the test.

Field evidence remains limited

The review found that most device evaluations took place in laboratories. Just six devices had published field evaluations: the GPHF-Minilab, CD3/CD3+, TruScan RM, a lateral-flow immunoassay dipstick, CBEx and Speedy Breedy. These studies varied in purpose and design, so their results should not be treated as a direct ranking of devices.

For example, the GPHF-Minilab combines visual inspection, TLC identification and semi-quantitative assessment with a disintegration test. Field studies showed that its performance depended on the test and the medicine being examined. In one multi-country evaluation, it detected 30% of a group of highly non-compliant antimalarial samples. Other findings showed that inspectors could mistake samples with substantially reduced API content for acceptable products, even after additional training. The Minilab can support screening, but these results illustrate why users need to understand the method’s limits and follow its procedures consistently.

The CD3/CD3+ uses different light sources to help compare packaging and dosage-unit appearance with authentic samples. In a field evaluation, it identified poor-quality antimalarials with high sensitivity, but specificity was lower: some authentic products were classified as poor quality. The review also noted that side-by-side comparison with a physical authentic sample could be more reliable than relying on library images alone.

Raman devices such as the TruScan RM and CBEx were also assessed in field settings. One evaluation reported strong discrimination between a set of poor-quality and authentic antimalarials using the TruScan RM. However, laboratory findings raised a separate concern: a match-or-fail identification result may not reliably distinguish a product with the correct API from one containing a different amount. Identifying an ingredient and measuring whether its quantity meets a specification are different tasks.

Match the tool to the decision

Before selecting a device, regulators and integrators should define what decision the screening result is meant to support. A tool designed to detect a missing or incorrect API may not be suitable for estimating API content. A packaging inspection device cannot confirm the chemical composition of a tablet. Consider the following questions when assessing options:

  • What does it measure? Establish whether the device screens the full formulation, targets particular APIs or examines physical characteristics.
  • What comparison does it require? Spectroscopic methods commonly rely on reference libraries; other tests may require reagents, consumables or authentic comparison samples.
  • How much preparation and training are involved? Some portable instruments need specialist setup or data processing before field use. The review describes training needs ranging from short instruction to more extensive preparation.
  • What evidence supports its use? Check whether performance was evaluated against an appropriate reference method and whether studies included relevant medicines and field conditions.
  • What happens after a result? Screening can help identify samples for further investigation, but confirmatory analysis may be necessary to establish medicine quality.

Cost and portability also vary. The review reported approximate purchase prices ranging from less than USD 10 to more than USD 20,000. Price alone does not show whether a device fits a particular surveillance workflow; consumables, sample handling, user skills and the type of result required also matter.

Build screening into a broader surveillance process

Portable devices can provide objective information beyond visual inspection, but no single technology addresses every quality question. The review found limited evidence for testing liquid, capsule and topical formulations, and for distinguishing between chiral molecules. It also identified gaps in independent evaluation, cost-effectiveness information and evidence about where along the pharmaceutical supply chain devices are best deployed.

For operations leaders and MRAs, the practical implication is to treat portable testing as one part of a quality-control pathway—not as a replacement for validated laboratory analysis. Select a device according to the screening question, verify that staff can use it consistently, and plan how suspicious results will be confirmed and acted on. Better comparative and field evaluation is needed to guide those choices and ensure screening tools support, rather than overstate, decisions about medicines quality.

Access Official Technical PDF

About The Author